# Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Source: https://onco.cc/trials/symbiotic-gi-03/  
OnCo record `symbiotic-gi-03` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing PF-08634404 in colorectal cancer, now recruiting.

## Summary

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer is a phase 3 interventional study registered as NCT07222800, led by Pfizer, and recruiting on the registry. Official title: An interventional, phase 3, double-blind, randomised study to evaluate the efficacy and safety of PF-08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatment-naïve participants with metastatic colorectal cancer. Planned enrolment is 800 participants (estimated). The study started in 2025-12-11 and primary completion is expected in 2030-03-29. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: Symbiotic-GI-03
- Tags: ctgov-ingest
- Registry id: NCT07222800
- Phase: 3
- Setting: An interventional, phase 3, double-blind, randomized study to evaluate the efficacy and safety of PF-08634404 in combination with chemotherapy versus bevacizumab in combination with chemotherapy in treatment-naïve participants with metastatic colorectal cancer
- Sponsor: Pfizer
- Enrolled: 800

## Sources

- ClinicalTrials.gov NCT07222800: https://clinicaltrials.gov/study/NCT07222800

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [PF-08634404](https://onco.cc/drugs/pf-08634404/)
- companies: [Pfizer (incl. Seagen)](https://onco.cc/companies/pfizer/)

---
JSON: https://onco.cc/api/v1/entities/symbiotic-gi-03.json